Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens

Lancet. 1984 Apr 21;1(8382):874-6. doi: 10.1016/s0140-6736(84)91340-0.

Abstract

Neutralising antibody responses to six post-exposure regimens of human diploid cell strain rabies vaccine with or without human rabies immune globulin (HRIG) were studied in 98 patients. The total amount of vaccine used was 22-34% of that required by conventional regimens. Vaccine was given at multiple sites intradermally or subcutaneously with or without adjuvant. Antibody was detectable within 7 days of the first dose in all subjects only in the groups given 0.1 ml intradermally at 8 sites. From day 14 onwards all groups showed an excellent antibody response; there was little difference between the various regimens. Suppression of the response to 8-site intradermal vaccination by a large dose of HRIG could be prevented by giving the second dose of vaccine on day 7 rather than day 14.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / analysis
  • Child
  • Costs and Cost Analysis
  • Female
  • Humans
  • Immunization, Passive
  • Injections, Intradermal / methods
  • Injections, Subcutaneous / methods
  • Male
  • Middle Aged
  • Rabies / prevention & control
  • Rabies Vaccines / administration & dosage*
  • Time Factors
  • Vaccination / economics

Substances

  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Rabies Vaccines